Welcome to our dedicated page for VIVOS SEC filings (Ticker: RDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VIVOS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VIVOS's regulatory disclosures and financial reporting.
VIVOS INC President Brad Allan Weeks reported open-market purchases of company common stock. He bought 60,000 shares on July 21, 2026 and 32,000 shares on July 22, 2026, each at $0.05 per share, for a total of 92,000 shares acquired directly.
VIVOS INC President Brad Allan Weeks reported multiple acquisitions of Common Stock. He made open-market purchases totaling 60,000 shares on July 9–10, 2026 at $0.0800 per share and received stock grants totaling 247,270 shares in March and June 2026. Following these transactions, he directly owns 1,379,654 shares.
Vivos Inc CEO and President Michael K. Korenko reported an open-market purchase of 200,000 shares of common stock at $0.0571 per share on July 15, 2026. Following this transaction, he directly holds 11,285,090 shares of Vivos Inc common stock.
VIVOS INC President Brad Allan Weeks reported open-market purchases of company Common Stock. He bought 48,000 shares on July 9, 2026 and 12,000 shares on July 10, 2026, both at $0.08 per share. After these transactions, he directly holds 999,235 shares of Common Stock.
Vivos Inc. reported a larger quarterly loss while modestly growing early revenue as it develops its radionuclide cancer therapies. For the three months ended March 31, 2026, revenue was $36,068, up from $26,748, mainly from IsoPet® animal treatments and related products.
The company recorded a net loss of $1,184,845 versus $834,696 a year earlier, driven by operating expenses and a $651,628 loss on a warrant exchange. Cash was $2,525,782 with negative operating cash flow of $429,861. Management states there is substantial doubt about Vivos’ ability to continue as a going concern and estimates it needs about $3.0 million per year, or $9.0 million over 36 months, to fund planned activities.
To address this, Vivos continues to raise capital under its qualified Regulation A+ offerings, including new shares and warrants sold in March and April 2026. The company is advancing its IsoPet® veterinary business, pursuing FDA approval for RadioGel® human use, and building U.S. and Indian manufacturing and clinical infrastructure.
Vivos Inc CEO and President Michael K. Korenko, who also serves as a director, reported an open-market purchase of common stock. On May 11, 2026, he bought 150,000 shares of Vivos Inc common stock at $0.0618 per share. Following this transaction, his direct ownership increased to 11,085,090 common shares, indicating a modest addition to an already large personal stake in the company.
Vivos Inc
Vivos Inc. (RDGL) is a development‑stage radiation oncology device company focused on its Y‑90–based RadioGel® for humans and IsoPet® for animals. It reported strong operational traction in veterinary oncology, including a 1,200% year‑over‑year increase in IsoPet® therapies from 2024 to 2025, more than 100 treatments with zero reportable serious adverse events, and 17 certified clinics across the U.S. as of December 31, 2025.
To support growth and regulatory progress, Vivos is building a multi‑site manufacturing network, adding a domestic facility at the Applied Process Engineering Laboratory in Washington and pursuing an international site in India through its new subsidiary Vivos Scientific India LLP, which also advances human and animal trials there. The company strengthened its intellectual property with new patents and trademarks, including U.S. Patent No. 12,521,452 B2 protecting its hydrogel‑based Precision Radionuclide Therapy™ platform, and continues preparing an FDA Investigational Device Exemption resubmission for RadioGel® with guidance from a specialized regulatory expert.
Financially, Vivos remains highly dependent on external capital. It had $1,558,525 in cash at December 31, 2025, an accumulated deficit of $88,427,246, and net losses of $3,066,017 in 2025, and its auditors expressed substantial doubt about its ability to continue as a going concern. The company estimates it needs about $3.0 million per year, or $9.0 million over 36 months, to fund operations, FDA processes, initial clinical trials, clinic activation, and manufacturing build‑out, and is relying heavily on successive Regulation A+ equity offerings and potential partnerships to proceed.